Hoth Therapeutics Inc (HOTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) has a cash flow conversion efficiency ratio of -0.733x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.05 Million) by net assets ($4.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HOTH net asset quality index to measure how much of total assets are equity-financed.
Hoth Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hoth Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore how much of Hoth Therapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Hoth Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hoth Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Immo Mcc NV
BR:MCC
|
N/A |
|
Grainger PLC
LSE:GRI
|
0.028x |
|
HaiNan Pearl River Holdings Co Ltd Class B
SHE:200505
|
-0.022x |
|
Mstns Co.Ltd
KQ:257370
|
-0.108x |
|
Destinasi Tirta Nusantara Tbk
JK:PDES
|
0.250x |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
-0.216x |
|
Citius Pharmaceuticals Inc
NASDAQ:CTXR
|
-0.019x |
|
Madhav Copper Limited
NSE:MCL
|
0.181x |
Annual Cash Flow Conversion Efficiency for Hoth Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hoth Therapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Hoth Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.15 Million | $-9.80 Million | -1.594x | -57.12% |
| 2024-12-31 | $6.88 Million | $-6.98 Million | -1.014x | -14.55% |
| 2023-12-31 | $9.54 Million | $-8.45 Million | -0.886x | +51.22% |
| 2022-12-31 | $5.12 Million | $-9.30 Million | -1.815x | -48.39% |
| 2021-12-31 | $9.88 Million | $-12.09 Million | -1.223x | +7.33% |
| 2020-12-31 | $4.65 Million | $-6.13 Million | -1.320x | +36.06% |
| 2019-12-31 | $2.40 Million | $-4.95 Million | -2.065x | +84.78% |
| 2018-12-31 | $154.97K | $-2.10 Million | -13.568x | -3354.39% |
| 2017-12-31 | $1.18 Million | $-465.24K | -0.393x | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more